Canget BioTekpharma LLC
CHINESE (中文版)


Expand page content
News
Year 2021:
Special News
  • Canget BioTekpharma Announces Exclusive Worldwide Agreement with Pinot Bio to Develop Antibody-Drug Conjugates

    - New Product Will Deliver High Payload to Drug Resistant Cancers

    Buffalo, NY— September 15, 2021 — Today, Canget BioTekpharma and PinotBio announced the signing of an agreement to develop new products that combine technologies from both companies to improve outcomes for patients with resistant cancers.

    Canget small molecule platform overcomes multiple mechanisms of drug resistance - “Canget platform compounds have demonstrated the ability to eliminate cancer and address multiple forms of drug resistance,” said Canget BioTekpharma CEO John J Seman. “Combining Canget technology with PinotBio expertise in the development of antibody drug conjugates will deliver increased amounts of antitumor drugs with enhanced targeting of treatment resistant cancers”.

    Antibody Drug Conjugates (ADC) - Antibody-drug conjugates are one of the fastest growing categories of anticancer drugs in the current pharmaceutical industry. The approach comprises a monoclonal antibody (mAb) conjugated to a small molecule via an appropriate chemical linker that is directed toward a target antigen expressed on the cancer cell surface. This technology will reduce systemic exposure of the small molecule drug and therefore, avoiding potential systemic toxicity. “Our ADC technology is highly targeted and can carry a powerful amount of drug directly to the surface of the targeted cancer cells.” said PinotBio CEO Doo Young Jung.

    International Opportunity - Under the terms of the agreement, PinotBio will develop one or more new ADC products with Canget drug platform technology, conduct all pre-clinical and clinical studies, and address all regulatory requirements for market approval. Canget BioTekpharma will be scientifically supportive in this process and providenon-GMP and GMP materials for development and commercialization.

    Canget BioTekpharma LLC (Canget) - Canget BioTekpharma LLC (701 Ellicott Street, Buffalo, NY 14203 USA) is a biopharma company, spun out from Roswell Park Comprehensive Cancer Center (www.roswellpark.org).

    PinotBio Inc. - PinotBio Inc. (http://www.pinotbio.com/en, 156 Gwanggvoro, Youngtonggu, Suwon – Republic of Korea) is a venture-backed Korea-based biotechnology company focused on the discovery and development of novel oncology therapies for a wide range of tumors.
Media News
  • Canget BioTekpharma LLC (Canget) Announces Exclusive Worldwide Agreement with PinotBio to Develop Antibody-Drug Conjugates (Full press release) - see the above Special News
  • On August 5, 2021, some individual stakeholder/investors outside of New York State came to Buffalo and visited Canget research laboratory and other facilities in the New York State Center of Excellence (CoE) in Bioinformatics and Life Sciences
  • Canget BioTekpharma LLC (Canget) Board Members in the Buffalo area including the Canget CEO John S. Seman, CSO, Fengzhi Li, Board members, Martin Casstevans (business affair expert) and Brian Pettit (human resources expert) have gathered on July 8, 2021 at Buffalo for discussing a list of events that need to be moved forward. This includes the finished and financial partnership and out licensing deal status update, outside investment status update, pharmaceutical industry network update and the 2021 – 2022 Canget involvement investment meeting plan including federal funding competition plan.
  • The Canget CSO Fengzhi Li was invited as a keynote speaker in the Virtual United Conferences of Drug Development and Industrial Pharmacy (Webinar, April 7, 2021) and presented his keynote presentation entitled “Pharmacokinetic, pharmacodynamic and biomarker studies on a novel small molecule FL118 for treatment of pancreatic and colorectal cancer patients” ( United Conference ) (https://unitedpharma.us/united-conference-of-drug-development-and-industrial-pharmacy/)
  • Canget acts as the sponsor to support Dr. Lisa Holthof for the printing of her PhD thesis.
  • In early 2020, Canget has finished additional outside investment from individual USA investors.
Year 2020:
Year 2019:
Year 2018:
Year 2017:
Year 2016:
Year 2015:
Year 2014:
Year 2013:
Year 2012:
Publication
Year 2021
Year 2020
Year 2019
Year 2018
Year 2017
Year 2016
Year 2015
Year 2014
Year 2013
Year 2012
Year 2011

Canget BioTekpharma Company Copyright. All rights reserved.